Profit

BSE Code: | NSE Code: | ISIN: | Sector:

NSE
634.90
Change Change %
-13.95 -2.15%

Updated:21 Sep, 2018, 15:59 PM IST

BSE
635.50
Change Change %
-11.80 -1.82%

Updated:21 Sep, 2018, 16:01 PM IST

Research Report Detail

Brokerage
Analyst
Report Date Call Price@Call Target Price
Stop Loss
Current Status Time Horizon
Religare
N/A
05-05-2016 Hold 815.90 940.00
N/A
Closed Long (1Y)
05-05-2017

Religare maintains hold on Sun Pharmaceutical Industries

Sun Pharma's in-licensed molecule from Merck, Tildrakizumab (Tildra), evaluated for treating moderate-to-severe plaque psoriasis, has met primary endpoints in phase-3 clinical trials. This is an important milestone for Sun Pharma and paves the way for its NDA filing in CY17. Target price remains unchanged on factoring in losses from cessation of Keveyis sales, which was halted recently.

Top